NG‐350A is a novel transgene-armed vector that selectively replicates in tumor cells and expresses an agonistic anti-CD40 antibody In a phase 1 trial, IV NG‐350A drove sustained and dose-dependent cytokine… read more →
Publications
NG-641 is a novel tumor-selective adenoviral vector that expresses four potent immuno-stimulatory transgenes: a fibroblast activation protein-directed bi-specific T-cell activator antibody, CXCL9, CXCL10 and FNα2. Therapeutic approaches to re-programme immunosuppressive… read more →
Olmo Sonzogni, Daniel E. Zak, Maria Stella Sasso, Rochelle Lear, Alice Muntzer, Manuela Zonca, Katy West, Brian R. Champion & James B. Rottman
Victor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donas, Gordon C Jayson, Patricia Roxburgh, Raúl Márquez Vázquez, Agnieszka Michael, Antonio Antón-Torres, Richard Brown, David Krige, Brian Champion and Iain McNeish
Trial registration number NCT02028117.
Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG‑350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded… read more →
PsiOxus Therapeutics, Ltd. (PsiOxus), a clinical stage oncology company re-programming the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. (Nasdaq: BLUE) presented preclinical… read more →
T-SIGn cancer gene therapy and anti-EGFR CAR-T cells synergize in combination therapy to clear A549 lung tumor xenografts and lung metastases in NSG mice. Click here for the Poster
Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour* and Margaret R. Duffy
Journal for ImmunoTherapy of Cancer (2019) 7:320
Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD, Duffy MR, Seymour LW. EMBO Mol Med 9:1067-1087 (2017)
